XBiotech Stock (NASDAQ:XBIT)
Previous Close
$2.66
52W Range
$2.09 - $3.78
50D Avg
$2.48
200D Avg
$2.75
Market Cap
$81.71M
Avg Vol (3M)
$100.65K
Beta
0.80
Div Yield
-
XBIT Company Profile
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.